XML 22 R4.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenue:        
Total revenue, net $ 28,146 $ 29,662 $ 57,657 $ 62,427
Cost of revenue 15,734 16,597 32,702 36,055
Gross profit 12,412 13,065 24,955 26,372
Operating expenses:        
Selling and marketing 6,715 5,944 13,748 12,084
Research and development 2,239 559 3,605 1,229
General and administrative 4,024 4,358 8,243 8,984
Total operating expenses 12,978 10,861 25,596 22,297
Operating (loss) income (566) 2,204 (641) 4,075
Interest and other expense, net 21 92 5 88
(Loss) income before income taxes and equity in losses of unconsolidated affiliates (587) 2,112 (646) 3,987
Income tax (benefit) expense:        
Current income tax expense 28 12 72 29
Deferred income tax (benefit) expense (454) 203 (1,508) (94)
Total income tax (benefit) expense (426) 215 (1,436) (65)
Net (loss) income before equity in losses of unconsolidated affiliates (161) 1,897 790 4,052
Equity in losses of unconsolidated affiliates (127) 0 (308) 0
Net (loss) income after equity in losses of unconsolidated affiliates (288) 1,897 482 4,052
Net loss attributable to redeemable non-controlling interest (47) 0 (91) 0
Net (loss) income attributable to Heska Corporation $ (241) $ 1,897 $ 573 $ 4,052
Earnings Per Share [Abstract]        
Basic (loss) earnings per share attributable to Heska Corporation (in dollars per share) $ (0.03) $ 0.26 $ 0.08 $ 0.57
Diluted (loss) earnings per share attributable to Heska Corporation (in dollars per share) $ (0.03) $ 0.24 $ 0.07 $ 0.52
Weighted average outstanding shares used to compute basic (loss) earnings per share attributable to Heska Corporation (in shares) 7,486 7,226 7,463 7,146
Weighted average outstanding shares used to compute diluted (loss) earnings per share attributable to Heska Corporation (in shares) 7,486 7,850 7,956 7,781
Core companion animal        
Revenue:        
Total revenue, net $ 24,716 $ 26,644 $ 49,432 $ 53,463
Other vaccines and pharmaceuticals        
Revenue:        
Total revenue, net $ 3,430 $ 3,018 $ 8,225 $ 8,964